Table 1.
Demographic profile of patients grouped according to methotrexate dose.
| Control MTX (n = 119) | Group A (n = 44) | Group B (n = 27) | Group C (n = 49) | Group D (n = 11) | |
|---|---|---|---|---|---|
| Age (years) (mean ± SD) | 46.1 ± 10.5 | 46.2 ± 10.9 | 48.7 ± 11.2 | 50.7 ± 11.4 | 43.4 ± 11.1 |
| Sex ratio (M : F) | 01 : 07.5 | 01 : 03.9 | 01 : 03.5 | 1 : 06 | 1 : 10 |
| Smokers, m (%) | 24 (20.2) | 12 (27.3) | 3 (11.1) | 15 (30.6) | 3 (27.3) |
| RF positive, m (%) | 86 (72.3) | 34 (77.3) | 14 (51.8) | 32 (65.3) | 7 (63.6) |
| Disease duration in months (mean ± SD) | 76.4 ± 62.6 | 60.4 ± 55.0 | 87.5 ± 66.2 | 107.5 ± 70.4 | 74.2 ± 28.8 |
| DAS 28 score (mean ± SD) | 5.4 ± 1.4 | 4.1 ± 1.2 | 3.9 ± 1.0 | 4.3 ± 1.2 | 4.3 ± 1.2 |
Control MTX: patients who had not taken MTX.
Group A: patients on MTX < 7.5 mg/week.
Group B: patients on MTX > 7.5–15 mg/week.
Group C: patients on MTX > 15–22.5 mg/week.
Group D: patients on MTX > 22.5 mg/week.